With optimized conditions in hand, the substrate scope of the two arylations was explored as illustrated in Tables and. The mono-arylated adducts described in Table may have great utility since having a free acid offers flexibility to the practitioner as numerous downstream transformations can be conceived. As mentioned above (Figure ), such compounds would be challenging to prepare using polar-bond disconnections. All entries in Table were conducted using 500mg-1g of the starting bromoacids (2.4 mmol scale, 14a-h). Of the 31 adducts in Table , experimental preparations for 20 of them have not been disclosed before (as either acids, esters, or cyano analogs). As these structures are of high interest to the pharma sector, many of them are prophetically claimed in the patent literature. Diversely substituted (hetero)arenes were found to engage in this first coupling using the optimized protocol. For instance, acids 27-32 (bearing EDG or EWG) can be found in the medicinal chemistry patent literature and were previously accessed via enolate-based ring closure using a bis-electrophile followed by cyano/ester hydrolysis. In this regard, the mild nature of this cross-coupling is advantageous for products such as 32 bearing a para cyano group for which no downstream hydrolysis is needed.